Targeted prophylactic anticoagulation based on the TRiP(cast) score in patients with lower limb immobilisation: a multicentre, stepped wedge, randomised implementation trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Kaleido Biosciences Inc (KLDO) Announces Collaboration with Robert Jenq, M D , to Explore Potential of its Microbiome Metabolic Therapies in Preventing Febrile Neutropenia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” conference this afternoon at 12:15 p.m. MST. The presentation will provide an update on progress with the Kaleido MMT
TM platform, including a review of the K031 COVID-19 study interim data that were announced on January 14, 2021.
“We are pleased to have this opportunity to present our chemistry-driven approach to leverage the therapeutic potential of the microbiome and additional details of our interim analysis, including statistical analysis of the effects of KB109 on symptom resolution in patients with mild-to-moderate COVID-19,” commented Johan van Hylckama Vlieg, Ph.D.,